- Puma Biotechnology (NYSE:PBYI) jumps 5% before the bell on the heels of Monday night's neratinib call (see here).
- Meanwhile, the sell-side is busy one-upping each other with price target hikes.
- BofA is reportedly out lifting its price objective to $141. That looks like the third raise this month (see here and here).
- Market chatter suggests Leerink's target is now $144.
- Investors can probably expect more bullish calls to come.
Puma Biotechnology continues to climb as analysts giddy over neratinib
Recommended For You
About PBYI Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
PBYI | - | - |
Puma Biotechnology, Inc. |